MARC details
| 000 -LEADER |
|---|
| fixed length control field |
06759cam a2200217 4500 |
| 001 - CONTROL NUMBER |
|---|
| control field |
NMDX5906 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
120401t2010 xxu||||| |||| 00| 0 eng d |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER |
|---|
| International Standard Serial Number |
10584838 |
| 100 ## - MAIN ENTRY--PERSONAL NAME |
|---|
| Personal name |
Cozzi-Lepri, A. |
| 240 ## - UNIFORM TITLE |
|---|
| Uniform title |
<a href="Clinical Infectious Diseases">Clinical Infectious Diseases</a> |
| 245 ## - TITLE STATEMENT |
|---|
| Title |
Long-term probability of detecting drug-resistant HIV in treatment-naive patients initiating combination antiretroviral therapy |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. (IMPRINT) |
|---|
| Date of publication, distribution, etc. |
2010 |
| 500 ## - GENERAL NOTE |
|---|
| General note |
NMUH Staff Publications |
| 500 ## - GENERAL NOTE |
|---|
| General note |
50 |
| 520 ## - SUMMARY, ETC. |
|---|
| Summary, etc. |
<p class="MsoNoSpacing" style="text-align:justify"><strong><span lang="EN-US">BACKGROUND:</span></strong><span lang="EN-US"> Robust long-term estimates of therisk of development of</span><span class="apple-converted-space"><span lang="EN-US" style="font-size: 7.5pt; font-family: Arial, sans-serif;">&nbsp;</span></span><span class="highlight"><span lang="EN-US" style="font-size: 7.5pt; font-family: Arial, sans-serif;">drug</span></span><span class="apple-converted-space"><span lang="EN-US" style="font-size: 7.5pt; font-family: Arial, sans-serif;">&nbsp;</span></span><span lang="EN-US">resistance are needed for human immunodeficiency virus (HIV)-infectedpatients starting combination antiretroviral therapy (cART) regimens currentlyused in routine clinical practice.</span></p><p class="MsoNoSpacing" style="text-align:justify"><strong><span lang="EN-US" style="text-transform:uppercase;mso-ansi-language:&#xA;EN-US">METHODS:</span></strong><span lang="EN-US" style="text-transform:uppercase;&#xA;mso-ansi-language:EN-US"> </span><span lang="EN-US">We followed a large cohort of patients seen in 1 of 11 HIV clinics inthe United Kingdom after starting cART with nucleoside reverse-transcriptaseinhibitors and either a nonnucleoside reverse-transcriptase inhibitor (NNRTI)or a ritonavir-boosted protease inhibitor (PI/r). Survival analysis wasemployed to estimate the incidence of virological failure and of detected</span><span class="apple-converted-space"><span lang="EN-US" style="font-size: 7.5pt; font-family: Arial, sans-serif;">&nbsp;</span></span><span class="highlight"><span lang="EN-US" style="font-size: 7.5pt; font-family: Arial, sans-serif;">drug</span></span><span class="apple-converted-space"><span lang="EN-US" style="font-size: 7.5pt; font-family: Arial, sans-serif;">&nbsp;</span></span><span lang="EN-US">resistance.<span style="text-transform:&#xA;uppercase"></span></span></p><p class="MsoNoSpacing" style="text-align:justify"><strong><span lang="EN-US" style="text-transform:uppercase;mso-ansi-language:&#xA;EN-US">RESULTS:</span></strong><span lang="EN-US" style="text-transform:uppercase;&#xA;mso-ansi-language:EN-US"> </span><span lang="EN-US">Seven thousand eight hundred ninety-one patients were included; 6448(82%) started cART with an NNRTI and 1423 (17%) with a PI/r. The cumulativerisk of virological failure by 8 years was 28%. The cumulative probabilities ofdetecting any</span><span class="apple-converted-space"><span lang="EN-US" style="font-size: 7.5pt; font-family: Arial, sans-serif;">&nbsp;</span></span><span class="highlight"><span lang="EN-US" style="font-size: 7.5pt; font-family: Arial, sans-serif;">mutation</span></span><span lang="EN-US">,&gt; or =1 major nucleoside reverse-transcriptase inhibitor International AIDSSociety-United States of America (IAS-USA)</span><span class="apple-converted-space"><span lang="EN-US" style="font-size: 7.5pt; font-family: Arial, sans-serif;">&nbsp;</span></span><span class="highlight"><span lang="EN-US" style="font-size: 7.5pt; font-family: Arial, sans-serif;">mutation</span></span><span lang="EN-US">, &gt; or =1 major NNRTI IAS-USA</span><span class="apple-converted-space"><span lang="EN-US" style="font-size: 7.5pt; font-family: Arial, sans-serif;">&nbsp;</span></span><span class="highlight"><span lang="EN-US" style="font-size: 7.5pt; font-family: Arial, sans-serif;">mutation</span></span><span class="apple-converted-space"><span lang="EN-US" style="font-size: 7.5pt; font-family: Arial, sans-serif;">&nbsp;</span></span><span lang="EN-US">(in those starting an NNRTI), and&gt; or =1 major PI IAS-USA</span><span class="apple-converted-space"><span lang="EN-US" style="font-size: 7.5pt; font-family: Arial, sans-serif;">&nbsp;</span></span><span class="highlight"><span lang="EN-US" style="font-size: 7.5pt; font-family: Arial, sans-serif;">mutation</span></span><span class="apple-converted-space"><span lang="EN-US" style="font-size: 7.5pt; font-family: Arial, sans-serif;">&nbsp;</span></span><span lang="EN-US">(in those starting a PI) were 17%,14%, 15%, and 7%, respectively, by 8 years. The probability of detecting PImutations in people who started PI/r-based regimens was lower than that of detectingNNRTI mutations in those starting NNRTI-based regimens (adjusted relativehazard, 0.36; 95% confidence interval, 0.26-0.50; P&lt;.001). The risk ofdetecting nucleoside resistance did not vary according to whether an NNRTI or aPI/r was used in the regimen (adjusted relative hazard, 1.00; 95% confidenceinterval, 0.80-1.26; P=.98).<span style="text-transform:uppercase"></span></span></p><p class="MsoNormal" style="text-align:justify"><strong><span lang="EN-US" style="text-transform:uppercase;mso-ansi-language:&#xA;EN-US">CONCLUSIONS:</span></strong><span lang="EN-US" style="text-transform:uppercase;&#xA;mso-ansi-language:EN-US"> </span><span lang="EN-US">In patients who started modern cART in clinical practice in the UnitedKingdom, virological failure by 8 years was relatively common and wasparalleled by an appreciable risk of resistance detection, although thedetection rate of class-specific resistance was lower for those who started aPI/r-based regimen.<span style="text-transform:uppercase"></span></span></p> |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Phillips, A. |
| 710 ## - ADDED ENTRY--CORPORATE NAME |
|---|
| Corporate name or jurisdiction name as entry element |
UK Collaborative Group on HIV Drug Resistance |
| 710 ## - ADDED ENTRY--CORPORATE NAME |
|---|
| Corporate name or jurisdiction name as entry element |
UK CHIC Study Group |
| 856 ## - ELECTRONIC LOCATION AND ACCESS |
|---|
| Uniform Resource Identifier |
<a href="www.ncbi.nlm.nih.gov/pubmed/20353366">www.ncbi.nlm.nih.gov/pubmed/20353366</a> |
| 856 ## - ELECTRONIC LOCATION AND ACCESS |
|---|
| Uniform Resource Identifier |
<a href="http://cid.oxfordjournals.org/content/50/9/1275.long">http://cid.oxfordjournals.org/content/50/9/1275.long</a> |